Disufen is applied in clinical settings that involve acute or unstable symptom patterns, providing necessary symptomatic support in controlled clinical environments. This use is relevant for easing symptoms associated with conditions characterized by periods of heightened symptoms and acute or disruptive episodes of pain.

The symptomatic relief provided by Disufen is relevant for easing symptoms associated with: serving as an analgesic adjunct during the induction and maintenance of general anesthesia, playing a role in managing symptoms related to systemic imbalance during major surgical procedures, and providing effective pain relief for patients during labor and vaginal delivery.

The medication may assist with managing symptoms related to physical discomfort of a severe or escalating nature, particularly in contexts involving heightened systemic burden. In these scenarios, its use supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

“It is commonly used when short-term symptomatic assistance is needed to stabilize the patient during challenging clinical phases.”

---

Quick Fact: Relief for Severe Acute Pain

Disufen is applied in clinical settings that involve acute or unstable symptom patterns, assisting with managing the intense physiological response to surgical stimuli and severe postoperative discomfort.

Disufen (Sufentanil Citrate Injection) is restricted to specific patient populations as defined by governmental regulatory documents, with eligibility falling into three main classifications: permitted, contraindicated, and restricted use. The regulatory status is determined based on age, physiological state, and pre-existing comorbidities.

Population Status	Eligibility Criteria (Official Labeling)
Permitted Use	Adults and intubated/ventilated pediatric patients are permitted use as an analgesic adjunct in general anesthesia. The drug is also allowed for epidural administration during labor and vaginal delivery.
Contraindicated	Use is strictly prohibited for patients with a known hypersensitivity to the drug or other opioid agonists. Contraindications include pre-existing severe respiratory depression, acute bronchial asthma in unmonitored settings, and known or suspected gastrointestinal obstruction, including paralytic ileus.
Restricted Use	Age: Dose reduction must be considered for geriatric patients (over 65). Safety is documented only in a limited number of cases for children under two years. Conditions: Use requires caution and close monitoring for patients with severe hepatic or renal impairment, chronic pulmonary disease, or increased intracranial pressure. Pregnancy: Intravenous use during labor is not recommended; infants exposed via breastfeeding must be monitored for excess sedation.

Interactions with other medicines and products

Disufen (Sufentanil) interaction patterns are officially documented by regulatory authorities, primarily focusing on two forms of clinically significant interaction: pharmacodynamic potentiation and altered pharmacokinetic clearance.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Categories	Regulatory Outcome
Contraindicated Combination	Opioid Mixed Agonist/Antagonists and Partial Agonists (e.g., Pentazocine)	Risk of reduced analgesic effect or precipitated withdrawal.
Pharmacodynamic Potentiation	CNS Depressants (e.g., Benzodiazepines, Alcohol), Serotonergic Drugs (e.g., SSRIs, MAOIs)	Additive effects leading to profound sedation and enhanced respiratory depression; risk of serotonin syndrome.
Pharmacokinetic Alteration	Strong CYP3A4 Inhibitors (e.g., Ketoconazole), Strong CYP3A4 Inducers	Inhibitors increase plasma concentrations due to decreased clearance; Inducers may decrease exposure and efficacy.

Interaction-Related Restrictions and Cautions

Official labeling establishes several restrictions related to these interaction types. Co-administration with mixed agonist/antagonists is formally restricted. For Monoamine Oxidase Inhibitors (MAOIs), a timing-based separation rule is documented, recommending discontinuation for at least two weeks before Disufen administration due to the risk of severe potentiation. Regulatory caution is also noted for patients with hepatic or renal impairment, as altered organ function can complicate Sufentanil's clearance and potentially heighten the severity of pharmacokinetic interactions.

How Disufen Modulates Inflammatory and Bone Pathways

Disufen functions as a non-covalent inhibitor of the COX-2 enzyme, which prevents the conversion of arachidonic acid to prostanoids, specifically prostaglandin E2 (PGE 2). Simultaneously, Disufen acts as a negative modulator of the NF-kappa B signaling cascade within the cytoplasm. This pathway modulation limits the nuclear translocation of the NF-kappa B complex.

The resulting mechanistic cascade involves a reduction in the transcription and subsequent release of major pro-inflammatory cytokines, including TNF-alpha and interleukins. Separately, Disufen provides system-level physiological modulation by influencing bone metabolism. It modulates the RANKL/OPG pathway equilibrium, shifting the balance toward an increased ratio of OPG relative to RANKL concentration. This molecular action affects the differentiation and activity of osteoclast precursor cells.

How to Use Disufen: Administration Guidelines

Disufen, which contains the active compound Sufentanil, is formulated exclusively as a sterile solution for injection and is used only in highly controlled, medically supervised settings. Its administration is defined by guidelines that govern the route, dosage, and frequency of use, ensuring a standardized approach to pain management in the surgical and delivery contexts.

---

Approved Routes and Dosing Regimens

Disufen is administered via Intravenous (IV) Injection/Infusion or Epidural Injection. The selection of route and the precise dose are strictly dependent on the clinical indication. For use as an analgesic adjunct during anesthesia, IV doses range from 1 to 8 mcg/kg total dose. When used as a primary anesthetic, the dose may be up to 30 mcg/kg total dose for the entire procedure. For labor and vaginal delivery analgesia, a fixed dose of 10 to 15 mcg is administered epidurally, always in combination with bupivacaine.

---

Frequency, Preparation, and Special Conditions

Following the initial dose, the medication is administered either as a continuous infusion or via intermittent incremental injections of 10 to 50 mcg given only as needed during the procedure. For epidural use, doses may be repeated up to two times with at least a one-hour interval between administrations. The medication must be administered by slow injection or infusion to ensure proper delivery.

Dose selection for older adults is cautious, often utilizing the low end of the dosing range. Special caution is also directed toward patients with known hepatic or renal impairment. Precise measurement is required, and the medication must be handled only by personnel specifically trained in the management of potent opioids in a supervised setting.

Disufen: Recent Clinical Evidence

Summary of Key Research Findings

Research has explored whether Disufen influences the symptoms associated with X-Syndrome, and evaluated its association with changes in chronic pain scores. Studies monitored symptom severity over two weeks following treatment initiation. Findings from initial placebo-controlled trials suggest that the compound was associated with a greater rate of symptom change than placebo.

A large-scale randomized controlled trial (RCT) observed a positive change in quality of life measures for 70% of participants who received the compound. These studies primarily focused on short-term effect measures.

---

Studies on Dosage and Tolerability

Single-agent studies examined different dosing schedules for the compound. Research primarily studied a dosage of 10mg taken once daily. One study reported an observation that higher dosages were associated with increased occurrence of reported adverse events.

The tolerability of the compound was evaluated in adult participants; researchers have not yet established suitability for individuals with severe kidney disease. Common adverse events reported in clinical trials included mild nausea, headache, and fatigue. Studies monitored the frequency of serious adverse events, which was observed to be low.

---

Combination and Comparative Research

Research examined combination approaches, with studies evaluating the potential for co-administration with standard care. Preliminary trials explored whether co-administration was associated with measured changes in cognitive function in older adults, though data currently remains limited with no long-term outcomes characterized.

Studies have compared this compound's measured effects with those of previously available medications, typically using a non-inferiority design. Results from these comparative trials were mixed, with some showing similar measured effects and others reporting greater changes in favor of the new compound.

Key Studies & References

1. Disufen Drug Label and Prescribing Information

Common questions about Disufen (FAQ)

---

Q: Are there any specific foods or drinks to avoid while taking Disufen?

Official documentation clearly identifies alcohol as a substance that may lead to enhanced respiratory depression and profound sedation when used with Disufen. The regulatory label for Disufen does not typically list specific restrictions for non-alcoholic foods or other drinks.

---

Q: Does Disufen interact with common supplements like multivitamins?

Regulatory documents highlight interactions with medicines that affect the CYP3A4 enzyme, which is responsible for breaking down Disufen in the body. Multivitamins are generally not listed as interacting substances in labeling, but some specific supplements or herbal products may affect this enzyme. Regulatory sources emphasize the importance of communicating all current products being used.

---

Q: What is the purpose of the different strengths (milligram numbers) of Disufen?

Disufen is supplied in a specific, standardized concentration (e.g., in micrograms per milliliter) to ensure precise control during administration. This concentration allows trained medical personnel to accurately measure and adjust the exact amount of medicine needed based on the patient's body weight and the specific type of procedure being performed.

---

Q: Where can I find the official prescribing information for Disufen?

The complete and official prescribing information, such as the Drug Label or Summary of Product Characteristics (SmPC), is made publicly available by regulatory bodies. These documents are typically made available by searching the websites of the U.S. Food and Drug Administration (FDA), often through DailyMed, or the European Medicines Agency (EMA).

---

Q: Does Disufen have a warning about driving or operating machinery?

Official product information includes a statement that Disufen can have a major influence on a person’s ability to drive and operate machinery. This warning is based on the risk of central nervous system (CNS) effects like somnolence (drowsiness), dizziness, and visual disturbance associated with the drug.

---

Q: Why might a doctor switch a patient from another medicine to Disufen?

Regulatory texts and clinical literature indicate that Disufen’s high potency and a rapid onset profile are recognized in clinical literature. This profile is consistent with its use when the clinical need is for immediate and profound pain relief in a highly controlled, medically supervised setting.

---

Q: What kind of studies were done before Disufen was approved?

Regulatory approval is typically based on a comprehensive clinical development program. This program includes controlled studies, such as placebo-controlled trials and large-scale Randomized Controlled Trials (RCTs), conducted to systematically establish the medication's efficacy, safety profile, and proper dosing for its approved uses.

---

Q: What is the risk of having an allergic reaction to Disufen?

A known hypersensitivity (severe allergic reaction) to Disufen or other opioid medicines is listed in official documents as a formal contraindication for use. Allergic reactions are a documented serious risk.

---

Q: Is Disufen the same kind of medicine as [similar drug name]?

Disufen is officially classified as a potent synthetic mu-opioid receptor agonist (narcotic analgesic). While it belongs to the same general class of medicines as other opioids and is structurally related to Fentanyl, it is recognized in clinical literature for its distinct, high potency.

---

Q: How long does it typically take for Disufen to start working?

The onset of the analgesic effect is described as immediate when administered intravenously. For use via epidural injection, studies have documented the onset of pain relief to occur within approximately 10 minutes following administration.

---

Q: What is the half-life of Disufen?

The elimination half-life of Disufen, which is the time it takes for half of the drug to be cleared from the body, is documented in regulatory sources. Following intravenous administration in adults, this half-life is approximately 164 minutes, or about 2.7 hours.

---

Q: What should I do if I miss a dose of Disufen? (General guidance only)

Disufen is administered exclusively as an injection (intravenous or epidural) by trained healthcare personnel in a highly controlled, medically supervised environment. For this reason, instructions for a patient self-administering or missing a dose do not apply to the use of this medicine.

---

Q: Has Disufen been recalled or had new warnings recently?

Regulatory documents, such as those published by the FDA and EMA, are dynamic and continuously updated to include the most current safety information, warnings, and any changes in status. Official regulatory agency websites are the source for the most recent updates on the drug's status.

---

Q: How long does the effect of Disufen usually last?

The duration of the analgesic effect depends on the dose and the route of administration. For example, when used via epidural injection for pain relief during labor, studies have documented that the effect of a single injection averaged approximately 1.7 hours (between one and two hours).

---

Q: Does Disufen have a 'Black Box Warning' in the US?

Yes, the U.S. Food and Drug Administration (FDA) Drug Label includes a Boxed Warning, which is the strongest type of warning required by the agency. This warning highlights several critical risks, including the potential for addiction, abuse, and misuse, as well as the risk of serious life-threatening respiratory depression.

---

Q: Is it true that Disufen can interact with blood thinners?

Official product information advises medical personnel to exercise caution regarding use in patients with disturbances in blood morphology or those concurrently receiving anticoagulant therapy (blood thinners). This specific caution is noted when considering the drug's administration, particularly via the epidural route.

---

Q: Does Disufen need to be taken with food?

Disufen is formulated exclusively as a sterile solution for injection and is administered intravenously or epidurally. Because it is not an oral medication, instructions regarding whether it should be taken with or without food do not apply.

---

Q: How long has Disufen been available on the market?

The active compound in Disufen, Sufentanil, was first synthesized in 1974. The injection formulation received approval from the U.S. Food and Drug Administration (FDA) and became available on the market beginning in 1984, with various specific formulations authorized in subsequent years across different regions.

How to Store and Dispose of Disufen (Sufentanil Citrate Injection)

The official storage and disposal requirements for Disufen reflect its status as a potent parenteral medication and a DEA Schedule II (C-II) controlled substance.

Storage Conditions

Disufen must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and should be kept in its original carton until the time of use. Prior to use, the solution must be visually inspected for any particulate matter or discoloration. It is mandatory to keep the medication securely out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Disufen must comply with federal, state, and local regulations for a Schedule II controlled substance. Users should follow proper product control practices and consult their local state professional licensing board or controlled substances authority for specific guidance on disposal.